Day: June 21, 2024

CALGARY, Alberta, June 21, 2024 (GLOBE NEWSWIRE) — Carbeeza Inc. (“Carbeeza” or the “Company“) (TSXV:AUTO) (OTCQB: CRBAF) announces today that it has received a Statement of Claim filed by Northern Micro Inc. and IDX Systems Corp. in the amount of approximately $2,175,000, claimed in connection with alleged unpaid professional services and related matters. Carbeeza intends on defending the Statement of Claim. Carbeeza Inc.Carbeeza is a Canadian-based software company whose platform is targeted to the automotive marketplace. It is the first application to harness the power of Artificial Intelligence to accurately predict the best financing scenario for consumers, all while keeping the consumer anonymous. Using state-of-the-art technology, Carbeeza brings the process of buying a car right to the phone, tailor-made...

GONZALES, La., June 21, 2024 (GLOBE NEWSWIRE) — Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) today announced that it intends to release the results of its operations for the fourth quarter and full year of fiscal 2024 before the market opens on Friday, June 28, 2024. Olivia W. Elliott, President and Chief Executive Officer and Craig J. Demarest, Vice President and Chief Financial Officer, will host a teleconference at 8:00 a.m. Central Daylight Time on that day to discuss the Company’s results and answer appropriate questions. Interested individuals may join the teleconference by dialing (844) 861-5504 and asking to join the Crown Crafts, Inc. call. The teleconference can also be accessed in listen-only mode by visiting the Company’s website at www.crowncrafts.com. The financial information to be discussed during the teleconference...

TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean mass FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21 – 24, 2024 in Orlando,...

PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to New Mexico residents, first responders and others directly impacted by the devastating wildfires. Individuals in New Mexico who have been displaced or who cannot access medical care as a result of the fires can seek treatment from a licensed health care professional for any non-emergency illness by calling Teladoc Health directly at 855-225-5032. Individuals seeking physician-authorization for prescription refills of non-narcotic drugs can also get assistance. For emergencies, patients should call 911. “We encourage those impacted by the fires to continue to prioritize their health and safety, especially as patients may experience wildfire-induced...

MINNEAPOLIS, June 21, 2024 (GLOBE NEWSWIRE) — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced the voting results of its Annual General and Special Meeting of shareholders, which was held on Friday, June 21, 2024. At the Meeting, the number of directors on the board of directors of the Company for the ensuing year was fixed at five (5) by the shareholders and the following nominees for election as directors of the Company were elected by a majority of votes cast by the shareholders virtually present or represented by proxy at the Meeting:Dr. Kyle E. Kingsley Ross M. Hussey Victor E. Mancebo Judd T. Nordquist Josh RosenShareholders also...

Vancouver, British Columbia, June 21, 2024 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) announces that it has closed its non-brokered private placement previously announced on June 6 and June 7, 2024, consisting of 8,966,668 special flow-through common shares (the “CFT Shares”) at a price of $0.245 per CFT Share, for gross proceeds of approximately $2.2 million (the “Offering”). The CFT Shares qualify as “flow-through shares” within the ‎meaning of the Income Tax Act (Canada) (the “Tax Act”)‎. The aggregate gross proceeds raised from the Offering will be used before December 31, 2025 for general exploration expenditures which will constitute “Canadian exploration expenses” that will qualify as “flow-through critical mineral mining expenditures” (each as defined in...

SARASOTA, Fla., June 21, 2024 (GLOBE NEWSWIRE) — Trump Media & Technology Group Corp. (NASDAQ: DJT) (“TMTG” or the “Company”)—operator of the Truth Social platform, yet another of President Donald J. Trump’s iconic American brands—today announced that it expects to receive more than $69.4 million in proceeds from the cash exercise of warrants on June 20 and 21, 2024. Such cash exercise became available after the Securities and Exchange Commission (“SEC”) declared effective the Company’s registration statement on Form S-1 on June 18, 2024 (“Registration Statement,” File No. 333-278678). If all warrants covered by the Registration Statement are exercised for cash, TMTG may receive up to an aggregate of approximately $247 million in proceeds. Additionally, $40 million of restricted cash on the Company’s balance sheet will become...

VANCOUVER, British Columbia, June 21, 2024 (GLOBE NEWSWIRE) — Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., “Metasphere Labs” or the “Company“) (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is pleased to announce the signing of a definitive Software Development Agreement dated June 21, 2024 (the “Agreement”) with ARCannabis BC Ltd (“ARCannabis”), a prominent cannabis retailer based in British Columbia. This partnership aims to enhance the online cannabis shopping experience with the use of advanced virtual reality (VR) technology. Pursuant to the Agreement, Metasphere Labs will design, develop, and deliver a state-of-the-art VR virtual store for AR Cannabis, leveraging either ThreeJS or Unreal Engine to create an immersive 3D user interface. The virtual store will be accessible on Google Chrome,...

TORONTO, June 21, 2024 (GLOBE NEWSWIRE) — Nexus Industrial REIT (“Nexus” or the “REIT”) (TSX: NXR.UN) today announced the suspension of its Distribution Reinvestment Plan (the “DRIP”), effective July 16, 2024. The DRIP, which allowed eligible unitholders to reinvest all or a portion of their cash distributions into additional units of the REIT, will be suspended due to the low prevailing market unit price and the resulting unfavourable unitholder dilution. The REIT believes this action is in the best interest of its unitholders. Unitholders participating in the DRIP will receive their distributions in cash following the July 15, 2024 distribution until further notice. The REIT will continue to evaluate the DRIP and consider reinstating it when market conditions improve. Upon reinstatement of the DRIP, plan participants...

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART® and VYVGART Hytrulo franchise Management to host conference call on June 21, 2024 at 11:00pm CET (5:00pm ET) June 21, 2024, 4:40pm ET   Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo...